STAT3 and lung carcinoma: They summarized a large variety of STAT3 inhibitors which reverse cisplatin resistance in lung cancer, ovarian cancer, cervical cancer, breast cancer, laryngeal cancer, head and neck cancers, esophageal cancer, and hepatocellular carcinoma [52].